Cypherpunk Technologies Inc. (CYPH) - Net Assets
Based on the latest financial reports, Cypherpunk Technologies Inc. (CYPH) has net assets worth $242.22 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($294.82 Million) and total liabilities ($52.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $242.22 Million |
| % of Total Assets | 82.16% |
| Annual Growth Rate | 8.55% |
| 5-Year Change | -48.0% |
| 10-Year Change | 30.44% |
| Growth Volatility | 317.11 |
Cypherpunk Technologies Inc. - Net Assets Trend (2012–2024)
This chart illustrates how Cypherpunk Technologies Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cypherpunk Technologies Inc. (2012–2024)
The table below shows the annual net assets of Cypherpunk Technologies Inc. from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $35.05 Million | -41.72% |
| 2023-12-31 | $60.14 Million | +10.06% |
| 2022-12-31 | $54.64 Million | -49.35% |
| 2021-12-31 | $107.89 Million | +60.06% |
| 2020-12-31 | $67.41 Million | +1077.81% |
| 2019-12-31 | $5.72 Million | -37.62% |
| 2018-12-31 | $9.18 Million | -17.47% |
| 2017-12-31 | $11.12 Million | -- |
| 2016-12-31 | $0.00 | -- |
| 2015-12-31 | $26.87 Million | -41.85% |
| 2014-12-31 | $46.21 Million | +146.24% |
| 2013-12-31 | $18.77 Million | +43.30% |
| 2012-12-31 | $13.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cypherpunk Technologies Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44294800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.00K | 0.11% |
| Other Comprehensive Income | $-120.00K | -0.34% |
| Other Components | $502.50 Million | 1433.75% |
| Total Equity | $35.05 Million | 100.00% |
Cypherpunk Technologies Inc. Competitors by Market Cap
The table below lists competitors of Cypherpunk Technologies Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dedicare AB (publ)
ST:DEDI
|
$34.17 Million |
|
Samhwa Crown
KO:004450
|
$34.18 Million |
|
Level Biotechnology
TWO:3118
|
$34.20 Million |
|
Rotork PLC
LSE:ROR
|
$34.20 Million |
|
LIGHTON
PA:ALTAI
|
$34.15 Million |
|
JFB Construction Holdings Class A Common Stock
NASDAQ:JFB
|
$34.13 Million |
|
Candles Scandinavia AB Series B
ST:CANDLE-B
|
$34.11 Million |
|
Tocvan Ventures Corp
F:TV3
|
$34.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cypherpunk Technologies Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 60,141,000 to 35,048,000, a change of -25,093,000 (-41.7%).
- Net loss of 67,555,000 reduced equity.
- New share issuances of 39,999,000 increased equity.
- Other comprehensive income decreased equity by 226,000.
- Other factors increased equity by 2,689,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-67.56 Million | -192.75% |
| Share Issuances | $40.00 Million | +114.13% |
| Other Comprehensive Income | $-226.00K | -0.64% |
| Other Changes | $2.69 Million | +7.67% |
| Total Change | $- | -41.72% |
Book Value vs Market Value Analysis
This analysis compares Cypherpunk Technologies Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.94x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $17.59 | $0.87 | x |
| 2013-12-31 | $25.21 | $0.87 | x |
| 2014-12-31 | $38.95 | $0.87 | x |
| 2015-12-31 | $15.75 | $0.87 | x |
| 2016-12-31 | $-106.71 | $0.87 | x |
| 2017-12-31 | $12.10 | $0.87 | x |
| 2018-12-31 | $6.37 | $0.87 | x |
| 2019-12-31 | $2.53 | $0.87 | x |
| 2020-12-31 | $11.36 | $0.87 | x |
| 2021-12-31 | $12.57 | $0.87 | x |
| 2022-12-31 | $4.83 | $0.87 | x |
| 2023-12-31 | $2.94 | $0.87 | x |
| 2024-12-31 | $0.93 | $0.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cypherpunk Technologies Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-192.75%) is below the historical average (-103.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -59.22% | 0.00% | 0.00x | 1.35x | $-9.07 Million |
| 2013 | -97.64% | 0.00% | 0.00x | 1.11x | $-20.20 Million |
| 2014 | -55.08% | 0.00% | 0.00x | 1.05x | $-30.07 Million |
| 2015 | -78.54% | 0.00% | 0.00x | 1.05x | $-23.79 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.61 Million |
| 2017 | -267.40% | 0.00% | 0.00x | 2.61x | $-30.84 Million |
| 2018 | -252.19% | 0.00% | 0.00x | 2.08x | $-24.06 Million |
| 2019 | -60.21% | -35.60% | 1.11x | 1.52x | $-4.02 Million |
| 2020 | -5.02% | -33.69% | 0.14x | 1.04x | $-10.13 Million |
| 2021 | -37.62% | -2705.80% | 0.01x | 1.09x | $-51.38 Million |
| 2022 | -99.92% | 0.00% | 0.00x | 1.06x | $-60.06 Million |
| 2023 | -135.37% | 0.00% | 0.00x | 1.21x | $-87.43 Million |
| 2024 | -192.75% | 0.00% | 0.00x | 1.40x | $-71.06 Million |
Industry Comparison
This section compares Cypherpunk Technologies Inc.'s net assets metrics with peer companies in the Asset Management industry.
Industry Context
- Industry: Asset Management
- Average net assets among peers: $1,050,753,688
- Average return on equity (ROE) among peers: 29.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cypherpunk Technologies Inc. (CYPH) | $242.22 Million | -59.22% | 0.22x | $34.16 Million |
| Acadian Asset Management Inc (AAMI) | $87.10 Million | 97.59% | 7.07x | $1.86 Billion |
| AllianceBernstein Holding L.P. (AB) | $433.18 Million | 67.62% | 1.61x | $3.54 Billion |
| Associated Capital Group Inc (AC) | $898.30 Million | 4.93% | 0.04x | $78.56 Million |
| Abrdn Emerging Markets Equity Income Fund Inc (AEF) | $143.60 Million | 58.18% | 0.22x | $265.69 Million |
| AgriFORCE Growing Systems Ltd (AGRI) | $-40.08K | 0.00% | 0.00x | $194.14 Million |
| Alvarium Tiedemann Holdings Inc. (ALTI) | $782.49 Million | -21.16% | 0.62x | $385.27 Million |
| Affiliated Managers Group Inc (AMG) | $655.56 Million | 9.23% | 1.32x | $8.30 Billion |
| Ameriprise Financial Inc (AMP) | $6.29 Billion | 20.88% | 21.22x | $41.60 Billion |
| AMTD IDEA Group (AMTD) | $611.58 Million | 16.58% | 4.02x | $44.19 Million |
| Artisan Partners Asset Management Inc (APAM) | $603.76 Million | 36.82% | 1.33x | $2.65 Billion |
About Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more